This firm-fixed-price delivery order, valued at $90,784.00, was awarded by the National Institute on Drug Abuse (NIDA) to Murty Pharmaceuticals, Inc., a minority-owned small disadvantaged business focused on pharmaceutical research and manufacturing. The contract is for FY24 drug product stability studies in support of NIDA's efforts to develop medications for substance use disorders. This work is performed under NIDA's broader $7 million indefinite delivery contract with Murty Pharmaceuticals for pharmaceutical development and manufacturing. Additionally, Murty holds a spot on a $45 million NIH indefinite delivery/indefinite quantity (IDIQ) contract for drug formulation and manufacturing. The contract does not have a set-aside designation.
Generated 9/13/24, 9:37 AM